Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand(Harvard University), Leo I. Gordon(Northwestern University), Jane N. Winter(Northwestern University), Steven M. Devine(National Marrow Donor Program), Edmund K. Waller(Emory University), Reuven Or(Hadassah Academic College), Yi‐Bin Chen(Massachusetts General Hospital), James R. Mason(Sheba Medical Center), Hillard M. Lazarus(University Hospitals of Cleveland), David Andorsky(Sheba Medical Center), Rinat Rotem‐Yehudar(Tel Aviv University), Chitra Hosing(The University of Texas MD Anderson Cancer Center), David Avigan(Beth Israel Deaconess Medical Center), Arnon Nagler(Sheba Medical Center), David A. Rizzieri(Duke University), John M. Timmerman(Sheba Medical Center), Mark Kaminski(Sheba Medical Center), Stephanie A. Gregory(Sheba Medical Center), Joseph P. Uberti(Sheba Medical Center), H. Kent Holland(Sheba Medical Center), Joseph W. Fay(Sheba Medical Center), Edie Weller(Boston Children's Hospital), Edward D. Ball(Sheba Medical Center), Markus Y. Mapara(Sheba Medical Center)
Cited by 439
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k